Gland Pharma LTD

BSE: 543245 NSE: GLAND
Gland Pharma LTD - healthcare in Medchal Malkajgiri District Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24239TG1978PLC002276 Incorporated 20 March 1978 ROC Hyderabad HQ Medchal Malkajgiri District Hyderabad, Telangana, India
Active Listed - NSE: GLAND · BSE: 543245 Public Limited Company healthcare
Data last updated
Market Cap
₹47,431 Cr
GLAND · NSE
Share Price
₹2,874.40
-0.86% today
Revenue
₹6,431 Cr
FY 2025-26 · +11.0% YoY
EBITDA
₹1,605 Cr
Margin 25.0%
Net Profit
₹1,042 Cr
FY 2025-26 · +49.5% YoY
P/E (TTM)
41.8x
P/B 4.6x
ROE
10.5%
ROCE 14.6%
Debt / Equity
0.03
Interest cover 2.8x

About Gland Pharma LTD

Data last updated:

Gland Pharma LTD is a public limited company based in Medchal Malkajgiri District Hyderabad, Telangana, India, a subsidiary of Fosun Pharma Industrial Pte Ltd. It specialises in medical and laboratory equipment, a part of the broader healthcare sector. Incorporated on 20 March 1978, the company has been in operation for over 48 years.

Registered with ROC Hyderabad under CIN L24239TG1978PLC002276. Listed on BSE: 543245 and NSE: GLAND.

Capital: an authorised share capital of ₹56.3 Cr and a paid-up capital of ₹16.5 Cr. Formerly known as Gland Pharma Pvt Ltd. It is led by directors including Jia Ai Zhang and Naina Lal Kidwai.

Last AGM: 28 August 2025. Financial statements filed for year ended 31 March 2025. Office: Medchal Malkajgiri District Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹6,430.65 Cr, a growth of 14.5% compared to the previous year. The net worth stands at ₹10,358 Cr (up 13.19% YoY). Total assets are valued at ₹10,878 Cr (up 12.71% YoY).

The company has a workforce of approximately 4,769 employees as per the latest available data. It operates as a subsidiary of Fosun Pharma Industrial Pte Ltd.

The company is associated with 1 brand - Gland Pharma. As per MCA filings, the company has satisfied charges of ₹566.83 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glandpharma.com.

Company Details of Gland Pharma LTD
CIN L24239TG1978PLC002276
Registration Number 002276
Incorporation Date 20 March 1978
ROC Hyderabad
Listing Status Listed (BSE: 543245, NSE: GLAND)
Company Status Active
Date of Last AGM 28 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Fosun Pharma Industrial Pte Ltd
Compliance Status Active Compliant
Key People
Srinivas Sadu Whole-Time Director Jia Ai Zhang Director Naina Lal Kidwai Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    glandpharma.com
  • Social Media
  • Registered Address
    Sy.No.143 – 148 150 &151 Near Gandi Maisamma X Roads D.P.Pally Dundigal – Gandimais, Amma(M), Medchal Malkajgiri District Hyderabad, Telangana, India – 500043
  • Industry
    Healthcare, Medical & Laboratory Equipment
Company report
Gland Pharma LTD - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Gland Pharma LTD report

Financials, compliance, directors, charges, ownership and filings for Gland Pharma LTD in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Gland Pharma

Gland Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239TG1978PLC002276, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239TG1978PLC002276Current
U24239AP1978PLC002276Previous
U24239TG1978PLC002276Previous

Associated Brands with Gland Pharma

Gland Pharma operates one associated brand: Gland Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Gland Pharma
Generic injectable drugs are manufactured across therapeutic segments.glandpharma.com

Competitors & Alternatives of Gland Pharma

Brands and companies operating in the same space as Gland Pharma LTD include Exela Pharma, Luoxin Pharmaceutical Group, Summit Biosciences and 5 more.

CompetitorDescriptionLocationFounded
Exela Pharma Exela Pharma Sterile injectable pharmaceuticals are manufactured alongside CDMO services.Lenoir, United States, United States2005
Luoxin Pharmaceutical Group Luoxin Pharmaceutical Group Developer and manufacturer of pharmaceutical productsLinyi, China, China2006
Summit Biosciences Summit Biosciences Nasal spray drug products are developed, manufactured, and commercialized.Lexington, United States, United States2008
August Bioservices August Bioservices Diversified research services for clinical solutions are offered.Nashville, United States, United States2017
ApiJect ApiJect Medicine injectors are manufactured by ApiJect for medical applications.Stamford, United States, United States2015
Vetter Pharma Vetter Pharma CDMO specializing in aseptically prefilled syringe systems, cartridges and vials.Ravensburg, Germany, Germany1950
INCOG BioPharma Services INCOG BioPharma Services Injectable drug products are manufactured by this biopharma CDMO.United States2020
Nitin Lifesciences Nitin Lifesciences CMO of small volume parenteral injectablesKarnal, India, India1994

Business Activity of Gland Pharma

The main business activity of Gland Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details for Gland Pharma LTD

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Gland Pharma

Gland Pharma LTD is audited by S.R. Batliboi & Associates LLP for the financial year 2022.

NameStatusAppointment DateCessation Date
S.R. Batliboi & Associates LLPLockedLockedLocked
Premium access

Complete auditor history for Gland Pharma LTD

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Gland Pharma LTD

Gland Pharma has 8 current directors and 27 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Jia Ai ZhangDirector17 May 20215 Years 4 MonthsCurrent
Naina Lal Kidwai
Also directs: Upl Limited, Biocon Limited, Nayara Energy Limited and 1 more
Director17 May 20215 Years 4 MonthsCurrent
Essaji Goolam Vahanvati
Also directs: Agb Oils LLP, Bagh Tola Jungle Lodges LLP, R & V Legal Advisors LLP and 5 more
Director30 Sep 20206 Years 0 MonthsCurrent
Srinivas Sadu
Also directs: Sadu Advisory Services Private Limited
Whole-Time Director25 Apr 20197 Years 5 MonthsCurrent
Udo Jahannes Vetter
Also directs: Paschal Form Work (India) Private Limited
Director07 Feb 20188 Years 7 MonthsCurrent
Wei HuangDirector04 Nov 20241 Years 10 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Financials of Gland Pharma LTD FY 2025-26 filings available

Gland Pharma LTD reported revenue of ₹6,430.65 Cr (up 14.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹6,431 Cr
+14.5% YoY
EBITDA
₹1,605 Cr
+26.5% YoY
Profit After Tax
₹1,042 Cr
+49.5% YoY
Net Worth
₹10,358 Cr
+13.2% YoY
Total Assets
₹10,878 Cr
+12.7% YoY
Total Debt
₹284 Cr
-9.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,4315,6165,6653,6254,4013,4632,633
Revenue growth+11.0%+0.4%+63.1%-8.1%+33.8%+28.8%+9997.0%
EBITDA1,6051,2691,3339681,5101,302955
EBITDA margin+25.0%+22.6%+23.5%+26.7%+34.3%+37.6%+36.3%
Profit before tax1,4651,0631,1331,0551,6191,335993
Net profit1,0426977728211,208997760
Net profit margin+16.2%+12.4%+13.6%+22.6%+27.5%+28.8%+28.9%
EPS (₹)62.3542.4046.9047.4273.7560.9449.88
Balance sheet
Total assets10,8789,6529,2747,9657,1645,9103,654
Net worth10,3589,1518,7247,9597,1585,9033,646
Total debt2843143724.454.745.004.96
Cash & bank3,3592,5561,8393,7713,0933,0061,325
Net working capital6,1095,4254,4786,1725,1154,6112,488
Cash flow
Cash from operations1,031915997364791605701
Cash from investing1881,718(1,749)1,211(999)(1,520)(761)
Cash from financing(417)(433)(799)14.9234.901,238(6.87)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,8001,7431,6951,4871,5061,4251,3841,406
Revenue growth (YoY)+19.6%+22.3%+22.5%+5.8%+7.4%-7.3%-10.4%+2.4%
Other income61.2311163.1784.1657.5344.0358.4959.66
EBITDA489513411314368348360297
EBITDA margin+27.2%+29.4%+24.2%+21.1%+24.4%+24.4%+26.0%+21.1%
Depreciation11110910810610195.7696.3393.83
Interest4.3610.033.937.8211.507.4522.826.11
Profit before tax435506362284313288299257
Tax11813910110097.2610294.6193.24
Net profit317367261184215187205164
EPS (₹)19.2222.2315.8711.1513.0811.3212.429.93
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,5524,1164,1673,6174,4013,4632,633
Revenue growth+9.0%-3.1%+3.9%-8.2%+33.8%+28.8%+23.6%
EBITDA1,6391,4431,4099621,5111,302955
EBITDA margin+36.0%+35.1%+33.8%+26.6%+34.3%+37.6%+36.3%
Profit before tax1,7481,4661,4051,0481,6191,335993
Net profit1,3151,0881,0448151,209997760
Net profit margin+28.9%+26.4%+25.0%+22.6%+27.5%+28.8%+28.9%
EPS (₹)78.8866.1463.3447.1173.7860.9549.88
Balance sheet
Total assets10,8609,7839,0207,9597,1655,9103,654
Net worth10,8109,7558,9957,9537,1585,9033,646
Total debt2.755.233.664.454.745.004.96
Cash & bank3,1782,4331,5993,7673,0863,0051,325
Net working capital5,7895,2454,1586,1595,1084,6112,488
Cash flow
Cash from operations1,1351,0741,136368791605701
Cash from investing(74.03)1,582(2,918)1,211(1,007)(1,521)(761)
Cash from financing(316)(340)(7.40)14.9234.901,238(6.87)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2871,2621,1781,0741,0391,0301,0111,063
Revenue growth (YoY)+23.9%+22.4%+16.5%+1.1%+2.7%-12.3%-7.9%+5.2%
Other income58.8210660.2182.5954.7443.7265.0657.80
Total expenses813754780699680636620699
EBITDA474508397375359394391364
EBITDA margin+36.8%+40.2%+33.7%+34.9%+34.5%+38.3%+38.7%+34.2%
Depreciation43.9543.1144.5344.8443.7743.0743.7741.62
Interest0.696.170.503.977.443.4518.310.17
Profit before tax488565412409362391394380
Tax12314410510793.1210199.0198.10

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,8001,7431,6951,4871,5061,4251,3841,406
Revenue growth (YoY)+19.6%+22.3%+22.5%+5.8%+7.4%-7.3%-10.4%+2.4%
Other income61.2311163.1784.1657.5344.0358.4959.66
EBITDA489513411314368348360297
EBITDA margin+27.2%+29.4%+24.2%+21.1%+24.4%+24.4%+26.0%+21.1%
Depreciation11110910810610195.7696.3393.83
Interest4.3610.033.937.8211.507.4522.826.11
Profit before tax435506362284313288299257
Tax11813910110097.2610294.6193.24
Net profit317367261184215187205164
EPS (₹)19.2222.2315.8711.1513.0811.3212.429.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,4315,6165,6653,6254,4013,4632,633
Revenue growth+11.0%+0.4%+63.1%-8.1%+33.8%+28.8%+9997.0%
Other income316214170240224135139
Total expenses4,8254,3484,3322,6562,8912,1611,678
Employee cost1,6291,4021,257403339311278
EBITDA1,6051,2691,3339681,5101,302955
EBITDA margin+25.0%+22.6%+23.5%+26.7%+34.3%+37.6%+36.3%
Depreciation42437834514711098.7894.59
Interest33.2842.0026.207.455.243.417.18
Profit before tax1,4651,0631,1331,0551,6191,335993
Tax437364360274407338220
Net profit1,0426977728211,208997760
Net profit margin+16.2%+12.4%+13.6%+22.6%+27.5%+28.8%+28.9%
EPS (₹)62.3542.4046.9047.4273.7560.9449.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.4816.4816.4716.4716.4316.3615.50
Reserves & surplus10,3419,1348,7077,9427,1415,8873,631
Shareholders' funds (net worth)10,3589,1518,7247,9597,1585,9033,646
Minority interest0.000.000.000.000.000.000.00
Secured loans0.000.000.000.000.000.000.00
Unsecured loans2843143724.454.745.004.96
Total debt2843143724.454.745.004.96
Total liabilities10,8789,6529,2747,9657,1645,9103,654
Assets
Gross block6,7855,6135,0122,2952,0811,4311,348
Net block4,4924,1473,9471,5711,502954968
Capital work in progress342151238177191338188
Investments0.000.000.000.001550.000.00
Inventories1,7441,6851,6551,9451,1861,275756
Sundry debtors1,8911,5171,5598711,199671602
Cash & bank balances3,3592,5561,8393,7713,0933,0061,325
Loans & advances5321,025592313219172163
Total current assets7,5276,7835,6456,9015,6975,1242,846
Total current liabilities1,4181,3581,167728582512358
Net working capital6,1095,4254,4786,1725,1154,6112,488
Total assets10,8789,6529,2747,9657,1645,9103,654
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,5563571,909319492170236
Net cash from operating activities1,031915997364791605701
Net cash from investing activities1881,718(1,749)1,211(999)(1,520)(761)
Net cash from financing activities(417)(433)(799)14.9234.901,238(6.87)
Net change in cash8032,199(1,552)1,590(174)323(66.91)
Closing cash3,3592,5561,8393,7713,0933,0061,325
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%-0.9%+56.3%-17.6%+27.1%+31.5%+9997.0%
EBITDA growth+26.5%-4.8%+37.7%-35.9%+16.0%+36.3%+9997.0%
PBT growth+37.8%-6.2%+7.4%-34.8%+21.3%+34.4%+9997.0%
Net income growth+49.5%-9.7%-5.9%-32.1%+21.2%+31.2%+9997.0%
Revenue CAGR (3Y)+21.1%+8.5%+17.8%+11.2%---
EBITDA CAGR (3Y)+18.4%-5.6%+0.8%+0.5%---
Profitability & leverage
Net income margin+16.0%+12.4%+13.6%+21.6%+27.5%+28.8%+29.4%
Return on capital employed+14.6%+11.7%+13.4%+14.0%+24.8%+28.0%+27.4%
Return on net worth+10.5%+7.8%+9.3%+10.3%+18.6%+20.9%+21.2%
Debt / equity0.030.040.020.000.000.000.00
Long-term debt / equity0.010.010.010.000.000.000.00
Interest cover2.824.712.650.910.370.280.83
Efficiency & per share
Fixed asset turnover1.041.061.551.662.512.491.95
Inventory turnover3.753.363.152.323.583.413.48
Debtors turnover3.773.654.663.724.715.444.38
EPS (₹)62.3542.4046.9047.4273.7560.9449.88
Dividend per share (₹)20.0018.0020.000.000.000.000.00
Book value per share (₹)628.67555.40529.65483.23435.64360.86235.32
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2871,2621,1781,0741,0391,0301,0111,063
Revenue growth (YoY)+23.9%+22.4%+16.5%+1.1%+2.7%-12.3%-7.9%+5.2%
Other income58.8210660.2182.5954.7443.7265.0657.80
Total expenses813754780699680636620699
EBITDA474508397375359394391364
EBITDA margin+36.8%+40.2%+33.7%+34.9%+34.5%+38.3%+38.7%+34.2%
Depreciation43.9543.1144.5344.8443.7743.0743.7741.62
Interest0.696.170.503.977.443.4518.310.17
Profit before tax488565412409362391394380
Tax12314410510793.1210199.0198.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,5524,1164,1673,6174,4013,4632,633
Revenue growth+9.0%-3.1%+3.9%-8.2%+33.8%+28.8%+23.6%
Other income304215167240224135139
Total expenses2,9132,6742,7592,6542,8902,1611,678
Employee cost529439410400339311278
EBITDA1,6391,4431,4099621,5111,302955
EBITDA margin+36.0%+35.1%+33.8%+26.6%+34.3%+37.6%+36.3%
Depreciation17616916214711098.7894.59
Interest18.0722.847.847.415.243.417.18
Profit before tax1,7481,4661,4051,0481,6191,335993
Tax449376362273407338220
Net profit1,3151,0881,0448151,209997760
Net profit margin+28.9%+26.4%+25.0%+22.6%+27.5%+28.8%+28.9%
EPS (₹)78.8866.1463.3447.1173.7860.9549.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.4816.4816.4716.4716.4316.3615.50
Reserves & surplus10,7949,7398,9797,9377,1425,8873,631
Shareholders' funds (net worth)10,8109,7558,9957,9537,1585,9033,646
Secured loans0.000.000.000.000.000.000.00
Unsecured loans2.755.233.664.454.745.004.96
Total debt2.755.233.664.454.745.004.96
Total liabilities10,8609,7839,0207,9597,1655,9103,654
Assets
Gross block2,9152,7982,5802,2952,0811,4311,348
Net block1,6881,7451,6941,5711,502954968
Capital work in progress13842.21120177191338188
Investments3,2932,7902,3868.161630.550.00
Inventories1,2651,2541,2601,9451,1861,275756
Sundry debtors1,5211,1431,1718631,075671602
Cash & bank balances3,1782,4331,5993,7673,0863,0051,325
Loans & advances459937541313343172163
Total current assets6,4225,7674,5716,8885,6905,1232,846
Total current liabilities633522413729582512358
Net working capital5,7895,2454,1586,1595,1084,6112,488
Total assets10,8609,7839,0207,9597,1655,9103,654
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,4331161,905311492170236
Net cash from operating activities1,1351,0741,136368791605701
Net cash from investing activities(74.03)1,582(2,918)1,211(1,007)(1,521)(761)
Net cash from financing activities(316)(340)(7.40)14.9234.901,238(6.87)
Net change in cash7452,316(1,789)1,594(181)322(66.91)
Closing cash3,1782,4331,5993,7673,0863,0051,325
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%-1.2%+15.2%-17.8%+27.1%+31.5%+28.8%
EBITDA growth+13.6%+2.4%+46.4%-36.3%+16.0%+36.3%+39.2%
PBT growth+19.3%+4.3%+34.1%-35.3%+21.3%+34.5%+44.7%
Net income growth+20.9%+4.3%+28.0%-32.6%+21.3%+31.2%+63.4%
Revenue CAGR (3Y)+8.0%-2.2%+6.4%+11.2%+29.1%+28.8%+21.2%
EBITDA CAGR (3Y)+19.4%-1.5%+2.7%+0.2%+30.1%+34.5%+15.2%
Profitability & leverage
Net income margin+28.6%+26.5%+25.0%+21.5%+27.5%+28.8%+29.4%
Return on capital employed+17.1%+15.8%+16.7%+14.0%+24.9%+28.0%+30.6%
Return on net worth+12.6%+11.6%+12.3%+10.3%+18.6%+20.9%+23.8%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover1.241.790.630.910.370.280.83
Efficiency & per share
Fixed asset turnover1.591.531.711.652.512.492.05
Inventory turnover3.613.272.602.313.583.413.16
Debtors turnover3.423.564.103.735.045.444.75
EPS (₹)78.8866.1463.3447.1173.7860.9549.88
Dividend per share (₹)20.0018.0020.000.000.000.000.00
Book value per share (₹)656.11592.08546.13482.90435.68360.86235.32
Want more history and ratios?
You're viewing the latest exchange-filed financials for Gland Pharma LTD. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Gland Pharma LTD

Shareholding for the quarter ended Sep 2026: promoters hold 51.80%, foreign institutional investors hold 8.70%, domestic institutional investors hold 30.50% and retail and other public shareholders hold 9.10%.

Promoters: 51.80%DII (Domestic Institutional): 30.50%FII (Foreign Institutional): 8.70%Retail & Others: 9.10%
Sep 2026
QUARTER
51.80% Promoters
30.50% DII (Domestic Institutional)
8.70% FII (Foreign Institutional)
9.10% Retail & Others
Promoter holding - history
Now 51.80% · Sep 2026High 51.80% · Dec 2025Low 51.80% · Dec 2025
50%50.8%51.5%52.3%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 51.80%Mar 2026: 51.80%Jun 2026: 51.80%Sep 2026: 51.80%51.80%51.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters51.80%51.80%51.80%51.80%
Public48.20%48.20%48.20%48.20%

Charges & Borrowings of Gland Pharma

Open charges
₹0
Satisfied charges
₹566.83 Cr
Breakdown by lending institutions
Syndicate Bank₹292.53 Cr
The Bank of Nova Scotia₹140.00 Cr
Icici Bank Limited₹100.00 Cr
Export Import Bank of India₹30.80 Cr
Technology Development Board₹3.50 Cr
Latest charge details
DateLenderAmountStatus
10 Sep 2012Icici Bank Limited₹100 CrSatisfied
30 Jun 2012Syndicate Bank₹100 CrSatisfied
06 Sep 2005The Bank of Nova Scotia₹140 CrSatisfied
13 Dec 2004Syndicate Bank₹7.5 CrSatisfied
09 Sep 2004Export Import Bank of India₹10 CrSatisfied

Total charge records: 11 View all charges

Employees and EPFO Compliance at Gland Pharma

Gland Pharma LTD has a workforce of 4,769 employees as of Mar 31, 2024.

Employee count
4,769
Active EPFO establishments
1
Employee growth
1.86%
Premium access

Employee and EPFO history for Gland Pharma LTD

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Gland Pharma

Premium access

GST registrations and filing compliance for Gland Pharma LTD

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Gland Pharma

Premium access

Credit ratings, litigation, and regulatory alerts for Gland Pharma LTD

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Gland Pharma

Premium access

MSME payment history for Gland Pharma LTD

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Gland Pharma

Premium access

Corporate group structure for Gland Pharma LTD

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Gland Pharma

Premium access

MCA filings and documents for Gland Pharma LTD

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Gland Pharma

Directors
15 Jun 2026
William Robert Keller was appointed as a Additional Director on 15 Jun 2026 & has been associated with this company since 3 months 19 days.
Activity
28 Aug 2025
Gland Pharma Ltd last Annual general meeting of members was held on 28 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Gland Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
04 Nov 2024
Wei Huang was appointed as a Director on 04 Nov 2024 & has been associated with this company since 1 year 10 months.
Directors
30 Aug 2024
Wenjie Zhang was appointed as a Director on 30 Aug 2024 & has been associated with this company since 2 years 1 month.
Directors
17 May 2021
Jia Ai Zhang was appointed as a Director on 17 May 2021 & has been associated with this company since 5 years 4 months.

Recent News on Gland Pharma

Frequently Asked Questions about Gland Pharma LTD

Gland Pharma is an active public limited company in the healthcare sector based in Medchal Malkajgiri District Hyderabad, Telangana, India. It was incorporated on 20 March 1978 (48+ years old) and is registered under CIN L24239TG1978PLC002276. Listed on BSE: 543245 and NSE: GLAND. The company has 4,769 employees.

Gland Pharma reported revenue of ₹6,430.65 Cr for FY 2025-26 (up 14.5% YoY) based on consolidated financials.

The current directors of Gland Pharma are:

The primary industry of Gland Pharma is healthcare. The company specifically operates in medical and laboratory equipment. The company is currently active in this sector.

Yes. Gland Pharma is listed on both BSE (code: 543245) and NSE (symbol: GLAND).

Gland Pharma can be reached at the registered office: Sy.No.143 – 148 150 &151 Near Gandi Maisamma X Roads D.P.Pally Dundigal – Gandimais, AmmaM, Medchal Malkajgiri District Hyderabad, Telangana, India – 500043, or through the website glandpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available